EHA 2019 | PRM-151 for myelofibrosis
Srdan Verstovsek
Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the Phase II study of PRM-151 for myelofibrosis patients previously treated with or are ineligible for treatment with ruxolitinib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
Related videos

Challenges in myelofibrosis management
Andreas Reiter

New therapies for MPNs: an update before ASH
Claire Harrison

Myelofibrosis management: ruxolitinib, fedratinib, transplant
Ruben Mesa

Allo-transplant for myelofibrosis
Donal McLornan

BET Inhibitor CPI-0610 and ruxolitinib for myelofibrosis
Srdan Verstovsek
More from Srdan Verstovsek